Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy

Revised Response Criteria for Malignant Lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text

Medicine, Oncology, Pathology +15

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

DG Maloney, A.J. Grillo-López, David Bodkin et al. · Journal of Clinical Oncology · 1997 · 638 citations

Pharmacy, Hematology, Pharmacokinetics +17

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

Junji Hiraga, Akihiro Tomita, Takumi Sugimoto et al. · Blood · 2009 · 258 citations · Full text

Medicine, Immunology, Oncology +14

What's going on 新たに提唱された悪性リンパ腫における治療効果判定基準[Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; The International Harmonization project on Lymphoma 'Revised response criteria for malignant lymphoma']

洋行 小林 · Mebio oncology · 2007 · 242 citations

Medicine, Internal Medicine, Oncology +14